Received Sep 2, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | 2 | AMVB030A | — |
2nd dose received late; This non-serious case was reported by a nurse via call center representative and described the occurrence of drug dose administration interval too long in a female patient who received Men ACWY-CRM NVS (Menveo) (batch number AMVB030A, expiry date 30-APR-2025) for prophylaxis. Previously administered products included Menveo (1st dose received in JUL-2024 with batch number AMVA994Z and expiry date 30-APR-2025) and Menactra (received in 2019). In AUG-2025, the patient received the 2nd dose of Menveo. In AUG-2025, an unknown time after receiving Menveo, the patient experienced drug dose administration interval too long (Verbatim: 2nd dose received late). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK Receipt Date: 04-AUG-2025 The nurse called to inform that a patient that had already completed the Menactra. The patient received two doses of Menveo and the second dose was late which led lengthening of vaccination schedule.